Skip to content Skip to footer
Join our LinkedIn Group and be part of the conversation on AI in life sciences
Login
Login
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart and MadeAi, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

98 articles published Follow:
AI Agents Transform Regulatory Content

2026 Prediction #6: AI Agents Will Transform Regulatory Content into a Competitive Asset

BlogApril 28, 2026108Views0Likes0Comments
Introduction: The Next Wave of Pharma Innovation In the life sciences, regulatory content has always played a critical role, yet it has rarely been treated as a strategic asset. Documents such as clinical summaries, regulatory submissions, safety reports, and evidence dossiers are essential for compliance, but they are often viewed as static outputs rather than…

Read More

From Capability to Confidence: How to Build Trustworthy AI for RWE Generation in HEOR, Market Access, and Medical Affairs

Building Trustworthy AI for RWE Generation in HEOR, Market Access, and Medical Affairs

White PaperApril 21, 202696Views0Likes0Comments
AI adoption in life sciences keeps stalling at the same point when compliance, traceability, and validation requirements enter the room. Most pilots never make it to regulatory or payer decision-making. AI addresses exactly that gap by embedding governance, auditability, and human validation into every workflow, enabling HEOR, Market Access, and Medical Affairs teams to move…

Read More

i4

MadeAi™ Honored as a Winner in the 2026 Artificial Intelligence Excellence Awards

MadeAi Press ReleaseApril 17, 2026101Views0Likes0Comments
Achievement recognizes organizations, products, teams, and individuals delivering measurable results through artificial intelligence CAMBRIDGE, April 9, 2026—MadeAi, Inc. (MadeAi) today announced it has been named a winner in the 2026 Artificial Intelligence Excellence Awards, in the Generative AI category supporting life sciences. Presented by the Business Intelligence Group, the award recognizes organizations, products, teams, and…

Read More

roche

From Explainable AI Screening to Publication-Grade Evidence for Roche HEOR Team

Case StudyApril 7, 2026212Views0Likes0Comments
How do you screen thousands of abstracts with transparency and reproducibility using minimal training data? In this case study, MadeAi partnered with the Roche HEOR team to design and validate an explainable AI pipeline for title and abstract screening in a systematic literature review. Using a structured PICO-based framework, the team screened over 3,300 abstracts…

Read More

Agentic AI Driving the Next Phase of Continuous Evidence Generation in Pharma

2026 Prediction #4: Agentic AI Driving the Next Phase of Continuous Evidence Generation in Pharma

BlogMarch 31, 2026175Views0Likes0Comments
For years, the pharmaceutical industry has followed a familiar evidence cycle. Teams design a clinical trial, execute it, lock the database, analyze the results, and wait for another study to address remaining questions. They wait for post-market surveillance to reveal real-world outcomes and for regulators or payers to request additional data before reimbursement decisions. However,…

Read More